Efavirenz pharmacokinetics in cerebrospinal fluid and plasma over a 24-hour dosing interval.
We determined the pharmacokinetics of efavirenz in plasma and cerebrospinal fluid (CSF) over a 24-h dosing interval in a patient who had undergone a lumbar drain because of cryptococcal meningitis. Drug concentrations were determined by high-performance liquid chromatography-tandem mass spectrometry in paired CSF (n = 24) and plasma (n = 25) samples. The median plasma efavirenz concentration was 3,718 ng/ml (range, 2,439 to 4,952), and the median CSF concentration was 16.3 ng/ml (range, 7.3 to 22.3). The CSF/plasma area-under-the-curve ratio was 0.0044 corresponding to a CSF penetration of 0.44% of plasma.
Department of Infectious Diseases, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. aylin.yilmaz@gu.se
Aylin
A
Yilmaz
Victoria
V
Watson
Laura
L
Dickinson
David
D
Back
D000480:Alkynes; D019380:Anti-HIV Agents / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D000935:Antifungal Agents / Q000494:pharmacology; D019540:Area Under Curve; D048588:Benzoxazines / Q000097:blood / Q000134:cerebrospinal fluid / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D060085:Coinfection; D003455:Cryptococcus neoformans / Q000187:drug effects / Q000254:growth & development; D003521:Cyclopropanes; D006678:HIV / Q000187:drug effects / Q000254:growth & development; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D006207:Half-Life; D006801:Humans; D008297:Male; D016919:Meningitis, Cryptococcal / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged; D053719:Tandem Mass Spectrometry
D000480:Alkynes; D019380:Anti-HIV Agents; D000935:Antifungal Agents; D048588:Benzoxazines; D003521:Cyclopropanes; C098320:efavirenz